Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2017
Συγγραφείς:
Quach, Hang Fernyhough, Liam Henderson, Ross Corbett, Gillian Baker, Bart Browett, Peter Blacklock, Hilary Forsyth, Cecily Underhill, Craig Cannell, Paul others
